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INTRODUCTION 
The COVID-19 (Coronavirus disease 2019) pandemic 
caused by the highly infectious SARS-CoV-2 (severe acute res-
piratory syndrome coronavirus 2) has challenged public 
health at an unprecedented scale, causing the death of more 
than two million people worldwide so far (1). T cells perform 
essential functions in the control and elimination of viral in-
fections; CD8+ T cells are critical for efficient clearance of vi-
rus-infected cells, whereas CD4+ T cells are important for 
supporting both the CD8+ T cell response and B cell-mediated 
production of specific antibodies. Characteristics from the 
ongoing pandemic suggest that T cell recognition will be crit-
ical to mediate long-term protection against SARS-CoV-2 (2), 
as the antibody-mediated response seems to decline in fol-
low-up evaluation of convalescent patients, although it’s not 
yet understood how this affects the risk of re-infection and 
what antibody levels are required for disease protection (3–
5). Furthermore, studies of the closely related SARS-CoV in-
fection shows persistent memory CD8+ T cell responses even 
after 11 years in SARS recovered patients without B cell re-
sponses (6, 7), emphasizing the potential role of CD8+ 
memory T cells in long-term protection from coronaviruses. 
Several recent studies have reported robust T cell immun-
ity in SARS-CoV-2-infected patients (8–10), and unexposed 
healthy individuals also showed functional T cell reactivity 
restricted to SARS-CoV-2 (9 , 11–15). The observed T cell cross-
reactivity is hypothesized to derive from routine exposure to 
common cold coronaviruses (HCoV) (HCoV-OC43, HCoV-
HKU1, HCoV-NL63 and HCoV-229E) that widely circulate, 
with 90% of the human population being seropositive for 
these viruses (16, 17) and substantial sequence homology to 
the SARS-CoV-2 genome (18, 19). However, the influence of 
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such pre-existing immunity to the T cell recognition associ-
ated with COVID-19 disease is poorly understood. 
SARS-CoV-2 infection can result in mild to severe disease 
(including death), but also a large number of asymptomatic 
infections are described (20–22). The presence of pre-existing 
T cell immunity, represented by cross-reactive T cells, could 
have strong implications for how individuals respond to 
SARS-CoV-2 infection. However, their biological role upon 
encounter with SARS-CoV-2 infection remains unclear, and 
their contribution to disease protection needs to be deter-
mined. Furthermore, in severe clinical disease, cytokine re-
lease syndrome is reported, and might in some cases, be 
dampened by immunosuppressive medication or anti-IL6 an-
tibody therapy (23, 24). Such clinical characteristics point to 
a potential uncontrolled immune response with the involve-
ment of strong T cell activation. 
CD8+ T cells are activated by a specific interaction be-
tween the T cell receptor (TCR) and peptide-antigen pre-
sented by major histocompatibility complex I (MHC-I) 
molecules on the surface of virus-infected cells. Although 
SARS-CoV-2-specific immunity has been reported both in the 
context of COVID-19 and pre-existing T cells, the full spec-
trum of exact antigens (minimal peptide epitope) within the 
viral genome, associated with this immunity and their immu-
nodominance in SARS-CoV-2-infected patients is not fully de-
scribed. Using our large-scale T cell detection technology 
based on DNA-barcoded peptide-MHC multimers (25), we 
have mapped T cell recognition throughout the complete 
SARS-CoV-2 genome, identified the exact epitopes recognized 
by SARS-CoV-2-specific CD8+ T cells, and characterized im-
munodominance of these epitopes in COVID-19 disease. 
Broad T cell recognition toward SARS-CoV-2-derived pep-
tides was also identified in SARS-CoV-2 unexposed healthy 
individuals, with a large overlap in the peptide-MHC com-
plexes recognized in the two groups. However, T cell recogni-
tion was substantially enhanced in the patient group, with 
SARS-CoV-2-reactive T cells accounting for up to 27% of all 
CD8+ T cells. Furthermore, we have evaluated the phenotypic 
characteristics of SARS-CoV-2-specific T cells and correlated 
their activation signatures with disease severity. 
RESULTS 
SARS-CoV-2-specific CD8+ T cells recognize a broad 
range of epitopes 
To reveal the full spectrum of T cell immunity in COVID-
19 disease, we used a complete SARS-CoV-2 genome sequence 
(26) to identify immunogenic minimal epitopes recognized by 
CD8+ T cells. Using NetMHCpan 4.1 (27), we selected 2204 
potential HLA binding peptides (9–11 amino acids) for exper-
imental evaluation. These peptides were predicted to bind 
one or more of ten prevalent MHC-I molecules, including 
HLA-A (A01:01, A02:01, A03:01, and A24:02), -B (B07:02, 
B08:01, B15:01), and -C (C06:02, C07:01, and C07:02) loci, 
leading to a total 3141 peptide-MHC specificities for experi-
mental evaluation (Fig. 1A, Table S1). Epitope predictions is 
covering the full viral genome, with ORF1 being the largest 
gene region and hence including the highest number of pre-
dicted peptides (Fig. 1B). T cell reactivity toward these pep-
tides was analyzed for 18 COVID-19 patients. In this cohort, 
11 patients had severe disease requiring hospital care and 
seven patients had mild disease not requiring hospitalization. 
Blood samples were collected during the active phase of the 
infection, as close as possible after the first positive SARS-
CoV-2 test (Table S2). The mean HLA coverage that could be 
obtained using the ten selected MHC-I molecules was 3.1 
HLA per patient and patients were evaluated using on aver-
age 972 DNA-barcoded peptide-MHC (pMHC) multimers per 
patient (Fig. S1A) (25). Briefly, each pMHC complex is mul-
timerized on a PE- (Phycoerythrin) or APC- (Allophycocya-
nin) labeled dextran backbone and tagged with a unique 
DNA-barcode. DNA-barcoded pMHC multimers are then 
pooled to generate an HLA matching patient-tailored pMHC 
multimer panel, which is incubated with patient-derived 
PBMCs (peripheral blood mononuclear cells), and multimers 
bound to CD8+ T cells are sorted and sequenced to identify T 
cell recognition toward the probed pMHC complexes. For 
comparative evaluation, we also included 39 T cell epitopes 
from common viruses: cytomegalovirus (CMV), Epstein-Barr 
virus (EBV), and influenza (Flu) virus (CEF) (Table S3, Fig. 
1C). 
We found broad and strong SARS-CoV-2-specific CD8+ T 
cell responses in COVID-19 patients, contributing up to 27% 
of the total CD8+ T cells (Fig. 1D). A substantial selection of 
T cells specific to individual immunogenic epitopes measur-
ing up to 14% of the total T cells was detected in several pa-
tients (Fig. 1D, Fig. S2, and Table S4). In total, we 
identified T cell responses to 142 pMHC complexes corre-
sponding to 122 unique SARS-CoV-2 T cell epitopes across the 
ten analyzed HLAs (Fig. 1E) dominated by peptides with 
high-affinity binding to their corresponding HLA molecule 
(Fig. S1B). We also detected 25 T cell responses to CEF-
derived peptides across the 18 COVID-19 patients (Fig. 1E 
and Table S5). For the SARS-CoV-2-derived peptides, HLA-
A01:01, A02:01, and B15:01 presentation dominated in terms 
of the total number of identified epitopes as well as the “im-
munogenicity score” (i.e., the number of T cell responses nor-
malized to the number of probing pMHC multimers and the 
number of patients analyzed) (Fig. 1F). HLA-A03:01 and 
C07:01 specific peptides showed the least T cell reactivity 
(three epitopes each) despite being analyzed in nine and six 
patients, respectively (Fig. 1E). Most of the immunogenic 
epitopes were mapped to the ORF1 protein, followed by S and 
ORF3 proteins (Fig. 1, G and H, and Table S4). Given the 
size difference of the viral proteins, the immunogenicity score 
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was used to evaluate their relative contribution to T cell 
recognition. Based on such evaluation, we observe that pep-
tides derived from ORF3 displayed the highest relative im-
munogenicity (in terms of T cell recognition), followed by 
ORF1 protein (Fig. 1H). The overall frequency of SARS-CoV-
2-reactive T cells (the sum of estimated frequencies for all 
SARS-CoV-2-specific T cells) in individual COVID-19 patients 
showed a broad range of T cell involvement and variation in 
terms of T cell recognition to individual SARS-CoV-2 proteins 
(Fig. 1I). 
In summary, we report SARS-CoV-2-specific CD8+ T cell 
immunity toward several epitopes and substantially high 
presence of SARS-CoV-2-specific T cells in several COVID-19 
patients. The ORF1 protein contributes the most to T cell 
recognition of SARS-CoV-2, but is also by far the largest group 
of proteins. When protein size is considered, ORF3 and ORF1, 
are the viral regions most frequently recognized by CD8+ T 
cells. 
Strong immunodominance of SARS-CoV-2 derived pep-
tides in COVID-19 patients. 
Of the 122 epitopes recognized by T cells in the patient 
cohort, five were determined as ‘immunodominant’ based on 
the presence of T cell recognition in >50% in the tested sam-
ples with the given HLA molecule, and T detection identified 
in at least two or more patients (Fig. 2A). Surprisingly, in our 
patient cohort, none of the immunodominant epitopes were 
derived from the S protein, despite this being the second-larg-
est protein (Fig. 2B). Among the immunodominant epitopes, 
a very robust HLA-associated immunodominance was ob-
served for two of the epitopes: HLA-A01:01-TTDPSFLGRY-
specific (and its variant peptides TTDPSFLGRYM and 
HTTDPSFLGRY), with specific T cells detected in all five an-
alyzed patients (estimated frequency reaching up to 25% of 
total CD8+ T cells); and HLA-B07:02-SPRWYFYYL, with spe-
cific T cells observed in four of the five patients evaluated 
(estimated frequency up to 10%) (Fig. 2A, Table S4). To val-
idate the T cell responses identified for the two most immu-
nodominant epitopes (TTDPSFLGRY, and SPRWYFYYL), we 
determined the presence of these T cells using conventional 
fluorophore-labeled pMHC tetramers in seven COVID-19 pa-
tients. For both immunodominant epitopes, the frequency of 
T cells determined by the individually-labeled pMHC tetram-
ers correlated to the frequencies determined based on the 
DNA-barcode labeled MHC multimer reagents (at a range 
from 0.01% to 11% of the total CD8+ T cells) (Fig. 2, C and 
D). Next, we evaluated the cytokine secretion capacity of the 
SARS-CoV-2 specific T cells by stimulating PBMCs (same 
timepoint as used for T cell identification) with respective 
epitopes. SARS-CoV-2 peptide-induced secretion of IFN-γ 
and TNF-α was detected in all seven patients, confirming 
functional activation of T cells raised against dominant as 
well as non-dominant epitope (Fig. 2E, Table S6). 
Low-avidity recognition toward SARS-CoV-2-derived 
peptides in healthy individuals 
In order to examine the potential for pre-existing SARS-
CoV-2-reactive T cells, we next analyzed healthy individuals 
for T cell recognition against all 3141 SARS-CoV-2-derived 
peptides. We selected two healthy donor cohorts: the first co-
hort included SARS-CoV-2 unexposed healthy individuals 
(HD-1; n=18 individuals, PBMCs collected before the COVID-
19 pandemic), and the second cohort included healthcare 
staff at high-risk of SARS-CoV-2 exposure but who did not 
test positive (HD2; n=20 individuals, PBMCs collected during 
COVID-19 pandemic). CD8+ T cells from SARS-CoV-2 unex-
posed healthy individuals showed broad-scale T cell recogni-
tion toward SARS-CoV-2-derived peptides across the whole 
viral genome (Fig. 3A, Fig. S3, and Table S7). Cumulatively, 
214 SARS-CoV-2-derived peptides were recognized by T cells 
in 16 out of the 18 analyzed samples. The high-risk COVID-19 
healthy cohort showed similar T cell recognition toward 178 
SARS-CoV-2 epitopes (Fig. 3B, Table S7) in 15 of the 20 do-
nors. T cell recognition in healthy donors was directed 
equally toward ORF1 and S proteins, whereas ORF3 derived 
peptides was recognized less in the healthy donor cohort 
compared to the COVID-19 patient cohort (Fig. S3B). Inter-
estingly, the immunodominant T cell epitopes from ORF1 
identified in the patient cohort was not among the most prev-
alent responses in the healthy donors (Fig. S3C). 
Despite such broad T cell-recognition in both healthy do-
nor cohorts, the presence of SARS-CoV-2 recognizing T cells 
seems to be of low frequency with limited separation of the 
CD8+ T cells binding to the pool of DNA-barcoded pMHC 
multimers (Fig. S4A) and measured by significantly lower 
staining-index of the pMHC multimer binding in healthy do-
nors compared to patients (Fig. 3C). Consequently, a direct 
estimate of the frequency of the SARS-CoV-2 reactive T cell 
populations in the individual healthy donors was not feasible. 
The low frequency and limited separation of these T cells 
were confirmed by independent analysis using conventional 
pMHC tetramers for several individual epitopes in healthy 
donor PBMCs (Fig. S4B). Together, these data suggest a 
lower TCR avidity to the probed pMHC in healthy individuals 
compared to COVID-19 patients, which could represent po-
tential cross-reactivity from existing T cell populations poten-
tially raised against other coronaviruses (such as common 
cold viruses HCoV-HKU1, HCoV-229E, HCoV-NL63, and 
HCoV-OC43) that share some level of sequence homology 
with SARS-CoV-2, as suggested in recent reports (13, 17, 19). 
To further validate the presence of low frequency T cells 
in healthy donors, we expanded T cells in vitro from several 
COVID-19-unexposed healthy donors and measured T cell 
binding using conventional pMHC tetramers. Based on in 
vitro peptide-driven expansion pMHC tetramer binding T cell 
populations were verified in multiple donors, recognizing 
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SARS-CoV-2-derived peptides, including immunodominant 
epitopes across four HLAs (A01:01-TTDPSFLRGY, A02:01-
LLLLDRLNQL, A02:01-KLKDCVMYA, A24:02-FYAYLRKHF, 
and B07:02-SPRWYFYYL) (Fig. 3D). Although these T cell re-
sponses were of low frequency, a functional cytokine re-
sponse (measured by IFN-γ and TNF-α production) was 
observed in in vitro expanded T cell cultures when re-stimu-
lated with individual peptide epitopes or epitope pools (Fig. 
S5). Importantly, forty-one of the COVID-19 immunogenic 
peptides, including the immunodominant peptides, identi-
fied in the patient cohort were also recognized by T cells of 
healthy donors, this includes the two most frequently ob-
served epitopes of SARS-CoV-2: HLA-A01:01-TTDPSFLRGY 
and HLA-B07:02-SPRWYFYYL (Fig. 3E, Table S7). Alto-
gether, we show a full spectrum of T cell recognition toward 
SARS-CoV-2-derived peptides in healthy donors; this is de-
tected at low frequency and show characteristics of low-avid-
ity interaction based on the staining index of the pMHC 
multimer interaction. 
Enhanced activation profile of SARS-CoV-2-specific T 
cells associated with COVID-19 disease severity 
For phenotypic characterization of SARS-CoV-2-specific 
CD8+ T cells, we combined pMHC multimer analysis with a 
13-parameter antibody panel (Table S8) and evaluated the 
phenotype of the SARS-CoV-2-reactive T cell populations in 
COVID-19 patients and healthy donors. This furthermore al-
lowed us to evaluate whether the multimer-specific T cell pro-
file of the high-risk for COVID-19 healthy cohort (HD-2) has 
any distinct features compared to the unexposed cohort (HD-
1), despite both cohorts containing presumably unexposed in-
dividuals. Dimensional reduction using Uniform Manifold 
Approximation and Projection (UMAP) showed distinct clus-
tering of SARS-CoV-2 multimer-reactive T cells of the COVID-
19 patient cohort compared to the two healthy donor cohorts 
with higher expression of activation markers CD38, CD69, 
CD39, HLA-DR, CD57, and reduced expression of CD8 and 
CD27 (Fig. S6). Compared to both healthy donor cohorts, we 
observed that more SARS-CoV-2-reactive T cells from COVID-
19 patients expressed the activation markers CD38, CD39, 
CD69 and HLA-DR, and showed a late-differentiated effector 
memory profile of reduced CD27 (Fig. 4A). We did not ob-
serve activation of SARS-CoV-2-specific multimer-positive T 
cells in the high-risk COVID-19 healthy cohort, except for 
non-significant trends for reduced CD27 and increased CD57 
expression (Fig. 4A). SARS-CoV-2 reactive T cells in patients 
and healthy donor cohorts showed a similar distribution of 
memory subsets (determined by CCR7 and CD45RA expres-
sion); however, higher expression of T cell activation markers 
(Fig. S7) was observed in EM (effector memory) and TEMRA 
(terminally differentiated effector memory) subsets in pa-
tients. Furthermore, the highly activated and differentiated T 
cell phenotype in COVID-19 patients was distinct to SARS-
CoV-2-specific T cells and not observed for CEF-specific T 
cells detected in the same cohort (Fig. 4B). We also observed 
no difference in CEF-specific multimer positive T cells be-
tween the three cohorts in similar analysis (Fig. S8A). Addi-
tionally, we compared the expression of T cell activation 
markers in combination with the inflammatory response 
marker CD38 on multimer-positive CD8+ T cells across the 
three cohorts, which showed significantly enhanced expres-
sion of activation molecules (CD39, CD69, and HLA-DR) and 
PD-1 inhibitory receptor on CD38+ T cells only in the patient 
cohort (Fig. S8, B and C). 
We next evaluated the association of SARS-CoV-2-specific 
CD8+ T cells presence in the patient cohort related to their 
requirement for hospital care. No overall difference in the to-
tal number of recognized SARS-CoV-2-derived epitopes was 
observed between severely diseased patients requiring hospi-
talization (n=11 individuals) and patients with mild symp-
toms not requiring hospital care (outpatient; n = 7 
individuals) (Fig. 4C). For phenotype characterization, 23 
additional patient samples (total n=41 patients; Hospitalized 
n=21, Outpatients n=20) were analyzed using a patient HLA-
matching pMHC multimer library combined with 13-param-
eter antibody panel, similar to the initial 18 patients but with-
out resolving individual epitope specificities. Based on this 
extended cohort, a significantly higher frequency of SARS-
CoV-2-specific CD8+ T cells was observed in the hospitalized 
patients compared to outpatient samples (Fig. 4D). Further-
more, a significant increase in the fraction of such cells ex-
pressing CD38, CD39, HLA-DR and PD-1 was observed in the 
hospitalized patients (Fig. 4E). By measuring co-expression 
of immune activation markers, CD38 together with CD39, 
PD-1, and HLA-DR, a strong elevation in T cells expressing 
these combinations of activation markers was observed 
among the hospitalized patients (Fig. 4F). Taken together, 
the increased frequency and activation signature suggests a 
role for SARS-CoV-2-specific CD8+ T cells in severe COVID-19 
disease. 
We also examined the phenotype of CD8+ T cells specific 
to the two most immunodominant epitopes TTDPSFLRGY 
and SPRWYFYYL with respect to disease severity (in eight pa-
tients; four hospitalized and four outpatients) using conven-
tional pMHC tetramer-based evaluation of individual T cell 
specificities. Hospitalized patients displayed increased PD-1 
expression compared to the same T cell populations in the 
outpatients (Fig. S9A). Furthermore, a higher frequency of T 
cells reactive to these two SARS-CoV-2 immunodominant 
epitopes was observed in the hospitalized patients, but the 
functional evaluation upon peptide stimulation revealed that 
only a sub-fraction of these high-frequency T cells where re-
sponsive to antigen exposure (Fig. 4G, Fig. S9B). These data 
together with increased PD-1 expression suggests a functional 
impairment or selective inhibition of these high-frequent T 
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cell populations, as observed by a recent study (5). 
A fraction of SARS-CoV-2 epitopes share sequence ho-
mology with widely circulating common cold corona-
viruses 
Pre-existing T cell immunity, in the context of SARS-CoV-
2-reactive T cells in unexposed healthy individuals, has been 
reported by several studies (13–15, 17, 19), and it has been hy-
pothesized that this is due to the shared sequence homology 
between the SARS-CoV-2 genome and other common cold 
coronaviruses (HCoV-OC43, HCoV-HKU1, HCoV-NL63, and 
HCoV-229E). Having evaluated the full spectrum of minimal 
epitopes for T cell recognition, we sought to evaluate the se-
quence homology at the peptide level, and its association 
with the SARS-CoV-2 T cell reactivity we observed in healthy 
donors. First, we searched for immunogenic hot-spots across 
the full SARS-CoV-2 proteome by comparing the number of 
identified epitopes (in the patient cohort) to the total number 
of predicted peptides in any given region of the proteins. Gen-
erally, the epitopes were spread over the full length of the 
protein sequences, while clustering in minor groups through-
out all regions of the viral proteome (Fig. 5A). Regions indi-
cated by asterisk demonstrate significant enrichment of T cell 
recognition relative to the number of MHC-I-binding pep-
tides in a given region. Both the C- and N-terminal regions of 
the ORF1 seem to hold fewer T cell epitopes compared to the 
rest of this protein. When similarly mapping the T cell recog-
nition of SARS-CoV-2-derived peptides observed in healthy 
donors, we detected a comparable spread of T cell recognition 
in the healthy donor cohort. Interestingly, most T cell epitope 
clusters in the patient cohort coincide with T cell recognition 
in the healthy donor cohort. The few regions that distinguish 
the T cell recognition observed in healthy donors from that 
observed in patients include: the C- and N-terminal regions 
of ORF1; parts of the N; and in general, a higher level of T cell 
recognition to S. In these regions, T cell recognition in 
healthy donors exceeded the observation from COVID-19 pa-
tients (Fig. 5A). Interestingly, when evaluating the preva-
lence of T cell recognition for the epitopes identified in >25% 
of the patient (Fig. 2A, Table S9) or the healthy donor co-
hort (Fig. S3C, Table S9), we observed that most of these T 
cell responses frequently observed in COVID-19 patients are 
also detected in healthy donors, while a large fraction of 
epitopes dominating in healthy individuals were not detected 
in our patient cohort (Fig. 5B). However, several SARS-CoV-
2 reactivities that were identified only in the healthy donors 
in our study were shown to be present in COVID-19 patients 
analyzed by other studies (Table S9), which strongly points 
to a substantial degree of cross-recognition to SARS-CoV-2 
from pre-existing T cell populations, and that such popula-
tions might drive the further expansion of T cell responses to 
SARS-CoV-2 infection. 
To further elucidate the potential origin of such a cross-
reactive T cell population in the healthy donor cohort, we 
next evaluated the sequence homology of SARS-CoV-2 MHC-
I-binding peptides with the four common cold coronaviruses: 
HCoV-HKU1, HCoV-NL63, and HCoV-229E. With a variation 
limit of up to two amino acids in each peptide sequence, 15% 
of the total predicted peptides showed sequence similarity 
with one or more HCoV peptide sequence (Fig. 5C, grey pie). 
Among the T cell-recognized peptides, in both the patient and 
healthy donor cohorts, this fraction was comparable with 19% 
and 16%, respectively, of T cell recognized peptides sharing 
sequence homology with one or more HCoV (Fig. 5C). As an 
alternative approach, the similarities were calculated by ker-
nel method for amino acid sequences using BLOSUM62, in-
dicating comparable sequence similarity of peptides 
recognized by T cells and those not recognized in reference 
to HCoV. However, interestingly, peptides of lowest similarity 
to HCoV were not recognized by T cells in the patient cohort 
(Fig. S10). 
As T cell cross-recognition can often be driven by a few 
key interaction points, predominantly in the ‘core’ of the pep-
tide sequence (i.e., position 3–8) (28, 29), we restricted the 
sequence similarity to the core of the peptide that would be 
most likely to interact with the TCR (30). Based on the pro-
tein-core only, up to 74% of all the identified epitopes showed 
sequence homology to HCoV (one or more) (Fig. 5C), sug-
gesting these common cold viruses as a potential source of 
the observed low-avidity interactions in healthy donors. Fur-
ther, when evaluating peptides frequently recognized by T 
cells in both COVID-19 patients and healthy individuals, we 
find evidence of substantial homology, as exemplified with 
the peptide sequences listed in Fig. 5D. However, similar se-
quence homology is observed for the peptide sequences that 
are recognized only in the patient cohort (Fig. 5D). Thus, at 
present, our data points to substantial T cell cross-recogni-
tion being involved in shaping the T cell response to SARS-
CoV-2 in COVID-19 patients; however, we find no specific en-
richment of T cell recognition to peptide sequences with large 
sequence homology compared to the total peptide library be-
ing evaluated, and the responses identified exclusively in the 
patient samples are not more specific to SARS-CoV-2 com-
pared to those recognized in both cohorts. Interestingly, 
ORF1 displayed the highest T cell recognition immunogenic-
ity and also the highest sequence identity to HCoV (40%, as 
oppose to 22-34% for all other SARS-CoV-2 proteins, calcu-
lated using direct sequence alignment). Future studies seek-
ing to fully understand the role and origin of the underlying 
T cell cross-recognition will likely require an in-depth evalu-
ation of pre- and post-infection samples. 
DISCUSSION 
Several studies using overlapping peptide pools spanning 
different region of SARS-CoV-2 viral proteins have shown a 
broad range of T cell activation in convalescent COVID-19 
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patients (8, 9 , 11, 14, 15, 31–35). Our work now provides a de-
tailed characterization of minimal epitopes derived from the 
complete SARS-CoV-2 genome for their CD8+ T cell immuno-
genicity, immunodominance, and functional and phenotypi-
cal characteristics in COVID-19 patients and healthy donors. 
We identified CD8+ T cell responses to 122 epitopes in 18 
COVID-19 patients after screening for T cell recognition 
based on 3141 peptides derived from the full SARS-CoV-2 ge-
nome and selected based on their predicted HLA-binding ca-
pacity. Of these, a few immunodominant T cell epitopes were 
recognized in most of the patients. Strikingly, both dominant 
and subdominant T cell epitopes were cross-recognized by 
low-level pre-existing T cell populations in SARS-CoV-2 unex-
posed healthy individuals. We have observed that the SARS-
CoV-2 dominant epitopes mount very strong T cell responses, 
with up to 27% of all CD8+ lymphocytes recognizing a single 
epitope (two overlapping peptides with same peptide core). 
Initial analysis of SARS-CoV-2 unexposed individuals re-
vealed substantial presence of CD4+ and CD8+ T cells cross-
reactive to SARS-COV-2 peptides (11, 15, 17, 36–39). Longitu-
dinal analysis of cross-reactive and induced CD8+ T cells be-
fore and after SARS-CoV-2 infection has been followed in 
individual cases (39), but the role of pre-existing T cells in 
overall immune response and disease outcome is not yet es-
tablished. Using genome-wide screen of expanded T cells, a 
recent study reported cross-reactivity to SARS-CoV epitopes 
in COVID-19 patients but not to other commonly circulating 
coronaviruses (40). Our ex vivo evaluation of all 3141 SARS-
CoV-2-derived minimal epitopes in two healthy cohorts 
(COVID-19 unexposed and high-risk) shows extensive but 
low-frequency and low-avidity interaction with CD8+ T cells. 
Pre-existing immunity based on cross-reactive T cells can in-
fluence how the immune system reacts upon viral exposure, 
including through faster expansion of pre-existing memory 
cells upon initial exposure to viral infection. A similar out-
come and benefit of pre-existing T cell immunity have been 
shown in the case of flu pandemic virus H1N1 (41, 42). How-
ever, active stimulation of cross-reactive T cells could also 
lead to exhaustion of rapidly expanded T cells, similar to the 
higher PD-1 expression and reduced cytokine secretion of the 
SARS-CoV-2 immunodominant T cells observed by us and 
others (5, 43, 44). Additionally, hyperactivation of pre-exist-
ing T cells could contribute to short- and long-term disease 
severity via inflammation and autoimmunity, as increased 
production of IFN-γ by CD4+ and CD8+ T cells has been ob-
served in severe COVID-19 patients (45). Furthermore, it has 
been reported (46) that SARS-CoV-2 infection can be a trig-
gering factor for autoimmune reactions and severe pneumo-
nia with sepsis leading to acute respiratory distress syndrome 
(ARDS), bone-marrow affection with pancytopenia and or-
gan-specific autoimmunity (47–49). Importantly, pre-existing 
T cell immunity can influence vaccination outcomes, as they 
may induce a faster, but possibly selective immune response. 
The ORF1 protein regions are highly conserved within coro-
naviruses (50), and show the highest HCoV identity among 
SARS-CoV-2 proteins; and most of the immunodominant 
epitopes that we have identified belong to the ORF1 region. 
Thus, a detailed evaluation of these T cell epitopes could be 
of value in vaccine design. 
Most vaccine development efforts are currently focusing 
on mounting antibody responses to the spike protein, with 
limited focus on T cell immunity. This is due to the receptor 
binding domain (RBD) being the main target for neutralizing 
antibodies produced by B cells (51). However, several studies 
have pointed out relatively low antibody titers in COVID-19 
recovered patients (3, 52–54). In conditions, where antibody 
titers cannot sufficiently protect against infections T cell im-
munity may sustain the antibody responses and provide a di-
rect source of T cells for clearing virus-infected cells. For the 
involvement of T cell immunity in vaccine development, our 
data suggest that the inclusion of other virus proteins, such 
as ORF1 or 3, might be highly relevant. For now, the role of 
antibody- and T cell-mediated immune response post-natural 
infection or post-vaccination is not yet resolved and requires 
extensive longitudinal analysis comparing antibody and T 
cell kinetics to determine synergistic or specific effect in long-
term disease protection. 
T cell recognition of SARS-CoV-2-derived peptides in both 
COVID-19 patients and healthy donors has prompted us to 
understand the role of T cell cross-reactivity in controlling 
infections. In recent years, technology improvements in TCR 
characterization have allowed us to interrogate the TCR-
pMHC interaction from a structural approach, while obtain-
ing experimental information related to the peptide amino 
acids that are crucial to T cell recognition (55–60). Such ef-
forts have taught us that T cell cross-recognition is very diffi-
cult to predict, without knowing the precise interaction 
required for the given TCR, as even T cell epitopes with as 
low as 40% sequence homology can be recognized by a given 
TCR (30). Therefore, the underlining source of T cell cross-
reactivity might arise from a larger set of epitopes within the 
HCoV viruses, including sequences with larger variation than 
those evaluated here (i.e., maximum of two amino acid vari-
ants per peptide sequence/peptide core). 
While the T cell recognition itself was largely overlapping 
in identity between patients and healthy donors, the magni-
tude of the T cell responses and, in particular, the phenotype 
of SARS-CoV-2-specific T cells was substantially different. We 
detected a strong activation profile of SARS-CoV-2-specific T 
cells only in COVID-19 patients, and this strong ‘activation 
signature’ (high expression of CD38, CD39, PD1, HLA-DR) 
was further enhanced in patients requiring hospitalization. 
Such highly activated T cell responses should facilitate viral 
clearance, and hence our data further support the notion that 
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some severely affected patients might suffer from hyperacti-
vation of their T cell compartment as a consequence of their 
primary viral infection, which may even be cleared. Addi-
tional signs of functional impairment were observed and cy-
tokine secretion upon antigen stimulation was incomplete for 
the high-frequent populations of SARS-CoV-2 specific T cells. 
A limitation of current study relates to the lack of infor-
mation related to the precise date of infection. This may dif-
fer by up to 1 week, as symptoms and hence diagnosis can be 
delayed. Consequently, differences in T cell mobilization 
and/or activation may be observed as a function of time, 
which is not controlled in the present study. However, a 
measurement of symptoms prior first positive SARS-CoV-2 
test, indicates that samples were collected at approximately 
the same time relative to symptom onset in the two groups of 
patients, except for 3 patients from the ICU included later 
after infection. Additionally, although our T cell screening 
strategy allows for high-throughput epitope mapping, deter-
mination of individual responses can only be estimated fol-
lowing the barcode deconvolution strategy, in relation to the 
pool of pMHC multimer positive T cells upon sorting. For the 
healthy donor population, the separation was insufficient to 
precisely determine the frequency of this T cell population, 
while for the patient cohort, both measurements demon-
strated strong correlation with measurements of the individ-
ual responses using conventional pMHC tetramers. 
Taken together, COVID-19 disease drives substantial T cell 
activation, with T cell recognition of a large number of SARS-
CoV-2-derived peptides. There is also considerable T cell 
recognition of such peptides in healthy donors, arguing for 
cross-recognition, potentially from T cells raised against 
other coronaviruses. Importantly, the activation profile 
clearly distinguish patients from healthy individuals. Inter-
estingly, patients that required hospitalization for COVID-19 
demonstrated a significantly higher frequency of SARS-CoV-
2-specific T cells and with a more activated phenotype com-
pared to patients with milder disease. The data presented 
here support a role for T cell recognition in COVID-19 and 
hypothesize that such T cells are associated with COVID-19 
disease severity. Pre-existing T cell immunity likely influ-
ences the immune response to SARS-CoV-2, which could be 
leveraged to fight novel infections. 
MATERIALS AND METHODS 
Study design 
This study aimed to identify a full repertoire of CD8+ T 
cell-mediated immune response to SARS-CoV-2 infection. For 
a comprehensive evaluation, we determined potential T cell 
epitopes within the complete SARS-CoV-2 genome and ana-
lyzed the resulting 3141 peptides for their T cell recognition, 
immunodominance, breadth of the T cell response, func-
tional and phenotype of reactive T cells, and contribution in 
COVID-19 disease severity. We used a DNA-barcode based 
MHC multimer T cell detection technology in combination 
with a 13-parameter flow cytometry phenotyping panel for T 
cell identification in PBMCs in a cohort of 18 COVID-19 pa-
tients (composed of severe and mild disease) and compared 
with T cell recognition in two healthy donor cohorts (18 
COVID-19 unexposed individuals and 20 high-risk healthcare 
staff). To understand association of SARS-CoV-2 specific T 
cells in disease severity we included an additional 23 patients 
for T cell phenotype analysis. 
Clinical samples 
Approval for the study design and sample collection was 
obtained from the Committee on Health Research Ethics in 
the Capital Region of Denmark. All included patients and 
health care employees gave their informed written consent 
for inclusion. PBMC samples from 18 SARS-CoV-2-infected 
patients were used in this study. Blood samples were col-
lected as close as possible to the first COVID-19 positive test. 
The patient cohort included samples from individuals with 
severe symptoms who required hospital care (hospitalized; n 
= 11) and patients with mild symptoms not requiring hospital 
care (outpatient; n = 7). For hospitalized patients, we col-
lected full data from the medical record regarding disease 
course, age, gender, travel history, performance status, symp-
toms, comorbidity, medications, laboratory findings, diag-
nostic imaging, treatment, need of oxygen, need for intensive 
care, and an overall estimate of disease severity (Table S2). 
For outpatients, we used a questionnaire to collect data on 
comorbidity, travel history, medications, and performance 
status. 
SARS-CoV-2 infection was diagnosed by one of the four 
platforms; BGI (BGI Covid-19 RT-PCR kit), PantherFusion 
(Hologic), Roche Flow (Roche MagNA Pure 96, Roche Light-
Cycler 480 II real-time PCR), and Qiaflow (QIAsymphony or 
RotorGene, Qiagen). In the last three platforms, LightMix 
Modular SARS-CoV (COVID-19) E-gene (# 53-0776-96) has 
been used. The diversity of platforms used were due to supply 
issues. All platforms were validated using validation kits and 
panels from the Statens Serum Institute (SSI), Denmark. 
Most patients had more than one positive test for COVID-19. 
Swabs, sputum, and tracheal secretion were used depending 
on the setting. 
Patients were attempted for inclusion soon after diagno-
sis. The samples were collected within 2 weeks from COVID-
19 diagnosis (except for three patients who were at intensive 
care post diagnosis). The average number of days with symp-
toms before sample collection matches closely in the two pa-
tient cohorts (10.85 days for hospitalized group and 10.45 
days for outpatient group) (Table S2); however, it was not 
possible to determine the exact date of infection. 
For the pre-COVID-19 healthy donor cohort (n = 18), we 
used samples collected prior to October 2019 and obtained 
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from the central blood bank, Rigshospitalet, Copenhagen, in 
an anonymized form. Additionally, we included 20 health 
care employees from Herlev Hospital during the COVID-19 
pandemic, who were at high risk of SARS-CoV-2 infection but 
not detected to be positive, as a cohort to follow immune re-
sponses in a potentially exposed population. 
PBMCs from all three cohorts were isolated immediately 
after sampling using Ficoll-Paque PLUS (GE Healthcare) den-
sity gradient centrifugation and were cryopreserved thereaf-
ter at a density of 2–20 × 106 cells/mL. 
SARS-CoV-2 peptide selection 
Potential HLA class I binding peptides were predicted 
from the complete set of 8–11mer peptides contained within 
the Wuhan seafood market pneumonia virus isolate Wuhan-
Hu-1 (GenBank ID MN908947.3) to a set of ten prevalent and 
functionally diverse HLA molecules (HLA-A01:01, HLA-
A02:01, HLA-A03:01, HLA-A24:02, HLA-B07:02, HLA-B08:01, 
HLA-B15:01 HLA-C06:02, HLA-C07:01, HLA-C07:02) using a 
preliminary version of NetMHCpan 
4.1(http://www.cbs.dtu.dk/services/NetMHCpan/index_v0.p
hp)[PMID: 32406916]. For peptides predicted from ORF1 
protein, a percentile rank binding threshold of 0.5% was 
used, and for peptides derived from all other proteins, a 
threshold of 1% was used. Altogether, 2203 peptides were se-
lected, binding to one or more HLA molecules, generating 
3141 peptide-HLA pairs for experimental evaluation (Table 
S1). All peptides were custom synthesized by Pepscan Presto 
BV, Lelystad, The Netherlands. Peptide synthesis was done at 
a 2 μmol scale with UV and mass spec quality control analysis 
for 5% random peptides with estimated purity of 70-92% by 
the supplier. 
MHC class I monomer production 
All ten MHC-I monomer types were produced using meth-
ods previously described (61). Briefly, MHC-I heavy chain and 
human ß2-microglobulin (hß2m) were expressed in Esche-
richia coli using pET series expression plasmids. Soluble de-
natured proteins of the heavy chain and hß2m were 
harvested using inclusion body preparation. The folding of 
these molecules was initiated in the presence of UV labile 
HLA specific peptide ligands (62). HLA-A02:01 and A24:02 
molecules were folded and purified empty, as described pre-
viously (63). Folded MHC-I molecules were biotinylated using 
the BirA biotin-protein ligase standard reaction kit (Avidity, 
LLC- Aurora, Colorado), and MHC-I monomers were purified 
using size exclusion chromatography (HPLC, Waters Corpo-
ration, USA). All MHC-I folded monomers were quality con-
trolled for their concentration, UV degradation, and 
biotinylation efficiency, and stored at -80°C until further use. 
DNA-barcoded multimer library preparation 
The DNA-barcoded multimer library was prepared using 
the method developed by Bentzen et al. (25). Unique barcodes 
were generated by combining different A and B oligos, with 
each barcode representing a 5′ biotinylated unique DNA se-
quence. These barcodes were attached to phycoerythrin (PE) 
or allophycocyanin (APC) and streptavidin-conjugated dex-
tran (Fina BioSolutions, Rockville, MD, USA) by incubating 
them at 4°C for 30 min to generate a DNA-barcode-dextran 
library of 1325 unique barcode specificities. SARS-CoV-2 
pMHC libraries were generated by incubating 200 μM pep-
tide of each peptide with 100 μg/mL of respective MHC mol-
ecules for 1 hour using UV-mediated peptide exchange (HLA-
A01:01, A03:01, B07:02, B08:01, B15:01, C06:02, C07:01, and 
C07:02) or direct binding to empty MHC molecules (HLA-
A02:01 and A24:02). HLA-specific DNA-barcoded multimer 
libraries were then generated by incubating pMHC mono-
mers to their corresponding DNA barcode-labeled dextrans 
at 4°C for 30 min, thus providing a DNA barcode-labeled pep-
tide-MHC (pMHC) multimer specifically to probe respective 
T cell population. A similar process was followed to generate 
DNA-barcoded pMHC multimers for CEF epitopes (HLA-A 
and HLA-B) using APC- and streptavidin-conjugated dextran 
attached with unique barcodes. 
T cell staining with DNA-barcoded pMHC multimers 
and phenotype panel 
All COVID-19 patient and healthy donor samples were 
HLA genotyped for HLA-A, B, and C loci (IMGM Laboratories 
GmbH, Germany, next-generation sequencing) (Table S10). 
Patient and healthy donor HLA-matching SARS-CoV-2 and 
CEF pMHC multimer libraries were pooled (as described pre-
viously (25)) and incubated with 5–10 × 106 PBMCs (thawed 
and washed twice in RPMI + 10% FCS, and washed once in 
barcode cytometry buffer) for 15 min at 37°C at a final volume 
of 60 μL. Cells were then mixed with 40 μL of phenotype 
panel containing surface marker antibodies (Table S8) and 
a dead cell marker (LIVE/DEAD Fixable Near-IR; Invitrogen 
L10119) (final dilution 1/1000), and incubated at 4°C for 30 
min. Cells were washed twice with barcode cytometry buffer 
and fixed in 1% PFA. 
Cells fixed after staining with pMHC-multimers were ac-
quired on a FACSAria flow cytometer instrument (AriaFu-
sion, Becton Dickinson) and gated by the FACSDiva 
acquisition program (Becton Dickinson), and all the PE-
positive (SARS-CoV-2 multimer binding) and APC-positive 
(CEF multimer binding) cells of CD8+ gate were sorted into 
pre-saturated tubes (2% BSA, 100 μl barcode cytometry 
buffer) (Fig. S11A). Sorted cells belonging to each sample 
were then subjected to PCR amplification of its associated 
DNA barcode(s). Cells were centrifuged for 10 min at 5000 × 
g, and the supernatant was discarded with minimal residual 
volume. The remaining pellet was used as the PCR template 
for each of the sorted samples and amplified using the Taq 
PCR Master Mix Kit (Qiagen, 201443) and sample-specific for-
ward primer (serving as sample identifier) A-key36. PCR-
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amplified DNA barcodes were purified using the QIAquick 
PCR Purification kit (Qiagen, 28104) and sequenced at Prim-
Bio (USA) using the Ion Torrent PGM 314 or 316 chip (Life 
Technologies). 
DNA-barcode sequence analysis and identification of 
pMHC specificities 
To process the sequencing data and automatically identify 
the barcode sequences, we designed a specific software pack-
age, ‘Barracoda’ 
(https://services.healthtech.dtu.dk/service.php?Barracoda-
1.8). This software tool identifies the barcodes used in a given 
experiment, assigns sample ID and pMHC specificity to each 
barcode, and calculates the total number of reads and clon-
ally reduced reads for each pMHC-associated DNA barcode. 
Furthermore, it includes statistical processing of the data. De-
tails are given in Bentzen et al. (25). The analysis of barcode 
enrichment was based on methods designed for the analysis 
of RNA-seq data and was implemented in the R package 
edgeR. Fold changes in read counts mapped to a given sample 
relative to mean read counts mapped to triplicate baseline 
samples were estimated using normalization factors deter-
mined by the trimmed mean of M-values. P-values were cal-
culated by comparing each experiment individually to the 
mean baseline sample reads using a negative binomial distri-
bution with a fixed dispersion parameter set to 0.1 (25). False-
discovery rates (FDRs) were estimated using the Benjamini-
Hochberg method. Specific barcodes with an FDR < 0.1% 
were defined as significant, determining T cell recognition in 
the given sample. At least 1/1000 reads associated with a 
given DNA barcode relative to the total number of DNA bar-
code reads in that given sample was set as the threshold to 
avoid false-positive detection of T cell populations due to the 
low number of reads in the baseline samples. T cell frequency 
associated with each significantly enriched barcode was 
measured based on the % read count of the associated bar-
code out of the total % multimer-positive CD8+ T cells popu-
lation in patient samples. In healthy donors, the T cell 
recognition were identified based on barcode enrichment 
analysis, same as in patient samples, however, a frequency 
estimate of the corresponding T cell populations was not de-
termined for significant responses identified in healthy do-
nors due to insufficient separation of multimer positive cells. 
To exclude potential pMHC elements binding to T cells in a 
non-specific fashion, non-HLA-matching healthy donor ma-
terial was included as a negative control. Any T cell recogni-
tion determined in this samples was subtracted from the full 
data set. 
T cell expansion and combinatorial tetramer staining 
PBMCs from healthy donors were expanded in-vitro using 
pMHC-dextran complexes conjugated with SARS-CoV-2-
derived peptides and cytokines (IL-2 and IL-21) for 2 weeks 
either with single pMHC specificity or with a pool of up to 
ten pMHC specificities. PBMCs were expanded for 2 weeks in 
X-vivo media (Lonza, BE02-060Q) supplemented with 5% hu-
man serum (Gibco, 1027-106). Expanded cells were used to 
measure peptide-specific T cell activation or stained using 
pMHC tetramers to detect T cells recognizing SARS-CoV-2 
epitopes. 
In-vitro expanded healthy donor PBMCs were examined 
for SARS-CoV-2 reactive T cells using combinatorial tetramer 
staining (64). Individual HLA-restricted pMHC complexes 
were generated using direct peptide loading (HLA-A02:01 
and A24:02) or UV-mediated peptide exchange (all other 
HLAs) as described above and conjugated with fluorophore-
labeled streptavidin molecules. For 100 μL pMHC monomers, 
9.02 μL (0.2 mg/mL stock, SA-PE-CF594 (Streptavidin - Phy-
coerythrin/CF594; BD Biosciences 562318), SA-APC (Bio-
legend 405207) or 18.04 μL (0.1 mg/mL stock, SA-BUV395 
(Brilliant Ultraviolet 395; BD 564176), SA-BV421 (Brilliant Vi-
olet 421; BD 563259), and SA-BV605 (Brilliant Violet 605; BD 
563260) of streptavidin conjugates were added and incubated 
for 30 min at 4°C, followed by addition of D-biotin (Sigma) at 
25 μM final concentration to block any free binding site. 
pMHC tetramers for each specificity were generated in two 
colors by incubating pMHC monomers and mixed in a 1:1 ra-
tio before staining the cells. Expanded cells were stained with 
1 μL of pooled pMHC multimers per specificity (in combina-
torial encoding) by incubating 1–5 × 106 cells for 15 min at 
37°C in 80 μL total volume. Cells were then mixed with 20 μL 
antibody staining solution CD8-BV480 (BD B566121) (final 
dilution 1/50), dump channel antibodies (CD4-FITC (BD 
345768) (final dilution 1/80), CD14-FITC (BD 345784) (final 
dilution 1/32), CD19-FITC (BD 345776) (final dilution 1/16), 
CD40-FITC (Serotech MCA1590F) (final dilution 1/40), CD16-
FITC (BD 335035) (final dilution 1/64)) and a dead cell 
marker (LIVE/DEAD Fixable Near-IR; Invitrogen L10119) (fi-
nal dilution 1/1000) and incubated for 30 min at 4°C. Cells 
were then washed twice in FACS buffer (PBS+2% FCS) and 
acquired on a flow cytometer (Fortessa, Becton Dickinson). 
Data were analyzed using FlowJo analysis software. 
T cell functional analysis 
For functional evaluation of T cells from PBMCs of 
COVID-19 patients or PBMCs expanded from healthy donors, 
1–2 × 106 cells were incubated with 1 μM of SARS-CoV-2 min-
imal epitope or pool of up to ten epitopes (1 μM/peptide) for 
9 hours at 37°C in the presence of protein transport inhibitor 
(GolgiPlug; BD Biosciences, 555029; final dilution 1/1000). 
Functional activation of T cells was measured using intracel-
lular cytokines IFN-γ (BD Bioscience, 341117; final dilution 
1/20) and TNF-α (Biolegend, 502930; final dilution 1/20). 
Cells incubated with Leukocyte Activation Cocktail (BD Bio-
sciences, 550583; final dilution 1/500) were used as a positive 
control, and HLA-specific irrelevant peptides were used as 
negative controls. Surface marker antibodies CD3-FITC (BD 
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Biosciences 345764 (final dilution 1/20)), CD4-BUV395 (BD 
Biosciences 742738 (final dilution 1/300), CD8-BV480 (BD Bi-
osciences B566121 (final dilution 1/50)), and dead cell marker 
(LIVE/DEAD Fixable Near-IR; Invitrogen L10119) (final dilu-
tion 1/1000)) were used to identify CD8+ T cells producing 
intracellular cytokines (Gating strategy, Fig. S5A). 
Flow cytometry analysis 
For phenotype analysis, all samples were analyzed using 
FlowJo data analysis software (FlowJO LLC). Frequencies of 
specific cell populations were calculated according to the gat-
ing strategy shown in Fig. S11B. For combinatorial tetramers 
staining, T cell binding to specific-pMHC tetramers was iden-
tified using the gating plan described in the original study 
(65). For UMAP analysis (66), FCS files of samples from the 
patient and healthy cohorts were concatenated (160,000 total 
cells), downsampled (FlowJo plugin), and visualized using 
UMAP (Version 2.2, FLowJo plugin) analysis based on the se-
lected markers; CD3, CD4, CD8, CD38, CD39, CD69, CD137, 
HLA-DR, PD-1, CCR7, CD45RA, CD27, and CD57. 
Sequence homology analyses 
To evaluate the homology between SARS-CoV-2 and 
HCoV, both epitopes (peptides recognized by T cells) and lig-
ands (peptide not recognized by T cells) were mapped to their 
respective source protein from the SARS-CoV-2 proteome. 
Enrichment analysis of the epitopes in the given region of the 
proteins was based on testing whether the count of observed 
epitopes exceeded what we expected from the number of lig-
ands tested at each position. Epitopes were considered suc-
cesses and the count of ligands were regarded as the number 
of trials in a binomial test. The probability of success was de-
rived from the average ratio of epitope to ligand per position 
across each protein. The test was ‘one-sided’ with a signifi-
cance level at 0.05. 
The similarity of SARS-CoV-2 ligands and epitopes from 
both patient and healthy donor cohorts to a set of human 
common cold corona viruses (HCoV-HKU1, HCoV-229E, 
HCoV-NL63, HCoV-OC43) was tested using two methods. The 
first approach utilized a kernel method for amino acid se-
quences using BLOSUM62 (67). The second approach was a 
simple string search allowing up to two mismatches. Based 
on the second approach each epitope was categorized by how 
many, if any, of the common cold viruses it would match 
with. Both methods were applied to the full peptide length 
and to the peptide core. 
Data processing and statistics 
T cell recognition was determined based on the DNA-
barcoded pMHC multimer analysis and evaluated through 
‘barracoda’ (see above). The data was plotted using python 
3.7.4. For all plots, peptide sequences with no significant en-
richments are shown as gray dots and all peptide with a neg-
ative enrichment are set to LogFc equal zero (Fig. 1, D, E and 
G; Fig. 3, A and B; Fig. S2). Box plots for data quantifica-
tion and visualization were generated, and their related sta-
tistical analyses were performed using GraphPad Prism 
(GraphPad Software Inc.) (Fig. 3C; Fig. 4A-F; Fig. S1, A 
and B, Fig. S7B, Fig. S8, B and C, Fig. S9A) or R studio 
(Fig. S10). For unpaired comparisons Mann-Whitney test 
was applied, and to compare more than two groups One-Way 
ANOVA (Kruskal-Wallis) test was performed using GraphPad 
Prism. All p values are indicated in figure legends. Flow Cy-
tometry data were analyzed using FlowJo (version 10). Im-
munogenicity scores (Fig. 1, F and H; Fig. S3) were 
calculated (as %) by dividing total identified T cell reactivity 
associated with a HLA or protein with the total number of 
specificities analyzed in a given cohort (number of peptides 
multiplied by number of patient with a given HLA). Staining 
index (Fig. 3C) was calculated as; ((mean fluorescence inten-
sity (MFI) of multimer+ cells – MFI of multimer- cells)/2 × 
standard deviation (SD) of multimer- cells)). MFI of multi-
mer+ and multimer- CD8+ T cells and the SD of the multimer- 
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Fig. 1. CD8+ T cell epitope mapping in SARS-CoV-2. (A) Schematic representation of the complete SARS-CoV-
2 genome used for the identification of 3141 peptides with predicted binding rank (NetMHCpan 4.1) of ≤0.5 
(ORF1 protein) and ≤1 (all remaining proteins) for ten prevalent HLA-A, B, and C molecules. (B) Bar plot showing 
the distribution of SARS-CoV-2 peptides related to their HLA-restriction (3141 peptide-HLA pairs) across the 
viral genome. Total peptide-MHC specificities analyzed for each protein are shown in parentheses next to the 
respective SARS-CoV-2 protein. (C) Experimental pipeline to analyze T cell recognition toward the SARS-CoV-
2-derived HLA-binding peptides in PBMCs using DNA-barcoded peptide-MHC (pMHC) multimers. A 13-
antibody panel was used for phenotype analysis of pMHC multimer positive CD8+ T cells. pMHC multimers 
binding CD8+ T cells were sorted based on PE (SARS-CoV-2-specific) or APC (CEF-specific) signal and 
sequenced to identify antigen-specific CD8+ T cells. (D) Representative analyses for SARS-CoV-2-restricted T 
cell populations in a COVID-19 patient. Left, flow cytometry plot of pMHC multimer staining of CD8+ T cells from 
a COVID patient stained with pMHC multimer panel showing SARS-CoV-2 (PE) and CEF (APC) multimer+ T cells 
that were sorted for DNA-barcode analysis to identify epitopes recognition. Right, CD8+ T cell recognition to 
individual epitopes were identified based on the enrichment of DNA barcodes associated with each of the tested 
peptide specificities (LogFc>2 and p <0.001, using barracoda). Significant T cell recognition of individual 
peptide sequences are colored based on their protein of origin and segregated based on their HLA-specificity. 
The black dot show CD8+ T cells reactive to one of the CEF peptides (here, CMV pp65; YSEHPTFTSQY-HLA-
A01:01). All peptides with no significant enrichments are shown as gray dots. (E) Summary of all the T cell 
recognition to SARS-CoV-2-derived peptides identified in the 18 analyzed COVID-19- patients. In parentheses, 
number of peptides tested for each HLA (upper row) and the number of patients analyzed for each HLA pool 
(lower row). Each dot represents one peptide-HLA combination per patient, and are colored according to their 
origin of protein, similar to shown in panel A. The black dots show CD8+ T cells reactive to the CEF peptides in 
all analyzed patients. (F) Bar plots summarize the number of HLA-specific SARS-CoV-2 epitopes identified and 
the HLA-restricted immunogenicity (% immunogenic peptides) in the analyzed patient cohort. Immunogenicity 
represents the fraction of T cell recognized peptides out of the total number of peptides analyzed for a given 
HLA-restriction across the HLA-matching donors (% normalized). (G) Similar to E, a summary of SARS-CoV-2-
specific T cell responses separated based on the protein of origin. (H) Bar plots show the number of epitopes 
derived from each of the SARS-CoV-2 protein and their immunogenicity score (% immunogenic peptides). (I) 
Estimated frequencies (% of total CD8+ T cells) as sum of all the SARS-CoV-2 epitope reactive T cells identified 
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Fig. 2. Strong immunodominance of SARS-CoV-2 derived peptides in COVID-19 patients. (A) The prevalence of 
T cell recognition toward the individual epitopes detected in COVID-19 patients. Dotted line indicates the epitopes 
determined as immunodominant, based on the presence of T cell recognition in more than 50% analyzed patients 
(marked in red throughout this figure). Bars are colored according to their protein of origin, similar as shown in Fig. 
1. (B) Pie chart of immunodominant epitopes distributed according to their protein of origin. (C) APC labeled pMHC 
tetramer-based analyses of CD8+ T cells in PBMCs of seven COVID-19 patients recognizing A01:01/TTDPSFLGRY 
or B07:02/SPRWYFYYL immunodominant epitopes. Gated population shows the percentage of T cells recognizing 
pMHC tetramers out of total CD8+ T cells. (D) Correlation of estimated T cell frequencies determined using DNA-
barcoded multimer estimation (Table S4) and using conventional tetramer analysis (panel C) for the two most 
immunodominant epitopes in seven COVID-19 patients. Spearman correlation (p =0.002, r =0.92). (E) Functional 
validation of SARS-CoV-2-specific T cell responses identified in COVID-19 patient samples. Flow cytometry plots 
showing intracellular cytokine staining of PBMCs from COVID-19 patients pulsed with selected SARS-CoV-2-derived 
peptides, selected based on the CD8+ T cell responses identified from the DNA-barcoded multimer analysis (Table 
S4). PBMCs from seven COVID-19 patients were analyzed for functional activation after stimulation with indicated 
peptides or with an HLA-matching irrelevant peptide (negative control). The numbers on the plot indicate the 
frequency (%) of CD8+ T cells positive for the analyzed cytokines, IFN-γ and TNF-α. The gating strategy of the flow 







































Fig. 3. Broad reactivity toward SARS-CoV-2-derived peptides in healthy individuals. (A) CD8+ T cell 
recognition to individual SARS-CoV-2-derived peptides (Table S7) and CEF peptides (Table S5) in the pre-
COVID-19 healthy donor cohort (n=18 individuals) identified based on the enrichment of DNA barcodes 
associated with each of the tested peptide specificities (LogFc>2 and p < 0.001, barracoda). Significant SARS-
CoV-2-specific T cell recognition of individual peptide sequences are colored and segregated based on their 
protein of origin. The black dots show CD8+ T cells reactive to the CEF peptides in all analyzed donors. (B) T 
cell recognition in the high-exposure risk healthy donor cohort (Tables S7 and S5) (n=20 individuals). (C) 
Staining index of CD8+ T cells binding SARS-CoV-2-specific pMHC multimers in the three evaluated cohorts. 
One-Way ANOVA (Kruskal-Wallis test) p <0.0001 (patient vs. HD-1 <0.0001, patient vs. HD-2 <0.0001); n=18 
(patient), n=18 (HD-1), and n=20 (HD-2). (D) Flow cytometry dot plots showing in-vitro expanded T cells from 
healthy donors recognizing SARS-CoV-2 derived epitopes, detected by combinatorial tetramer staining. T cell 
binding to each pMHC specificity is detected using pMHC tetramers prepared in a two-color combination (blue 
dots), gray dots show tetramer negative T cells, and the number on the plots shows the frequency (%) of 
tetramer+ of the CD8+ T cells. Gating strategy used for the flow cytometry analysis is shown in Fig. S11A. (E) 
Venn diagram illustrating the overlap of T cell recognition toward SARS-CoV-2-derived peptides in COVID-19 
patient and healthy donor cohorts. 
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Fig. 4. Enhanced activation profile of SARS-CoV-2-specific T cells correlates with COVID-19 disease severity. (A) Box plots 
comparing percentages of SARS-CoV-2 pMHC multimer binding CD8+ T cells expressing the indicated phenotype surface markers 
in the COVID-19 patient and the two healthy donor cohorts (n=18 individuals for each cohort). Each dot represents one sample. 
Frequencies were quantified from flow cytometry data processed using the gating strategy applied in Fig. S11. P-values for One-Way 
ANOVA (Kruskal-Wallis test): CD38 <0.0001 (HD-1 vs. patient <0.0001, HD-2 vs. patient <0.0001), CD39 <0.0001 (HD-1 vs. patient 
=0.006, HD-2 vs. patient <0.0001), CD69 <0.0001 (HD-1 vs. patient <0.0001, HD-2 vs. patient <0.0001), HLA-DR =0.002 (HD-1 vs. 
patient =0.02, HD-2 vs. patient <0.004), and CD27 =0.03 (HD-1 vs. patient =0.03). (B) Box plots comparing the percentage of SARS-
CoV-2 pMHC multimer+ (n=18 patients) and CEF pMHC multimer+ (n=14 patients) CD8+ T cells expressing the indicated surface 
markers in the COVID-19 patient cohort. Each dot represents one sample. P-values for hypothesis (Mann-Whitney) test: =0.0002 
(CD38), <0.0001 (CD39), 0.0001 (CD69), =0.009 (HLA-DR), =0.04 (CD27). (C) Number of SARS-CoV-2 epitopes recognized by T 
cells in outpatient (n=7) and hospitalized (n=11) patient samples. (D) Box plots show frequencies of SARS-CoV-2 multimer+ CD8+ T 
cells in outpatient (n = 20) and hospitalized patients (n=21). P-value (Mann-Whitney test) = <0.0001. (E) Box plots showing the 
percentage of SARS-CoV-2 pMHC multimer positive CD8+ T cells expressing the indicated surface markers in outpatients (n=20) 
and hospitalized patients (n=21). Each dot represents one sample. P-values for hypothesis (Mann-Whitney) test: =0.001 (CD38), 
=0.036 (CD39), <0.0001 (PD-1), and =0.027 (HLA-DR). (F) Comparison of the frequency of SARS-CoV-2 pMHC multimer+ CD8+ T 
cells expressing activation markers (CD39, and HLA-DR) and PD-1 in combination with CD38 (as shown in the representative plots 
(Fig. S8), in hospitalized and outpatient samples. P-values for hypothesis (Mann-Whitney) testing: =0.04 (CD38+ CD39+), = 0.005 
(CD38+ HLA-DR+), and <0.0001 (CD38+ PD-1+). (G) Comparison of tetramer binding (conventional single-color tetramers) and 
functional (cytokine secreting) T cells recognizing the two immunodominant epitopes in 10 patients, grouped according to COVID-
19 disease severity. 
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Fig. 5. A fraction of SARS-CoV-2 epitopes shares sequence homology with widely circulating common cold coronaviruses. (A) 
SARS-CoV-2 T cell immunogenicity map across the viral proteome comparing the distribution of identified SARS-CoV-2 epitopes 
(patient cohort, orange line; n=16 patients) with the total analyzed peptides (gray line). The height of a peak indicates the number of 
ligands (right y-axis) analyzed in a particular region and the number of identified epitopes (left y-axis). The lower panel similarly maps 
epitopes and ligands from healthy donors (green line, n=31 individuals). Positions significantly enriched (p-value <0.05) with 
epitopes compared to the number of tested ligands are marked with asterisk. (B) T cell epitopes selected based on their 
immunodominant characteristics either in the patient (orange) or healthy donor (green) cohort, or represented in both (red) is 
evaluated for their T cell recognition prevalence in both cohorts. (C) Sequence similarity SARS-CoV-2 peptides with the other four 
common cold coronaviruses (HCoV): HCoV-HKU1, HCoV-NL63, and HCoV-229E. The gray pie chart indicates the sequence 
similarity of total predicted peptides from SARS-CoV-2 with any one (+1), two (+2), three (+3), or all four (+4) HCoV peptides with a 
variation limit of up to two amino acids within the full-length peptide. The colored pie chart shows a similar analysis for epitopes 
detected in the patient (n=16) or healthy donor cohort (combined analysis of HD-1 and HD-2, n=31) for full-length peptide and peptide 
core. (D) Examples of sequence homology for shared (between patient and healthy donors) and patient-specific T cell epitopes with 
one or more HCoV peptide sequence. Non-matching amino acids are shown in gray. 
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